Evidence map›Paper›PMID 40555984›Full record

ArticleVirology journal2025

Evaluating enterovirus diversity among symptomatic patients in Hungary during and after easing the COVID-19 lockdown.

Nóra Deézsi-Magyar, Gyula Zsidei, Norbert Kiss, Bereniké Novák, Marianna Mezősi-Csaplár, Katalin Réka Tarcsai, Adrienne Lukács, Erzsébet Barcsay, Katalin Szomor, Mária Takács

Abstract read
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nóra Deézsi-MagyarDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary. magyar.nora@nngyk.gov.hu.
Gyula ZsideiDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Norbert KissDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Bereniké NovákDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Marianna Mezősi-CsaplárDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Katalin Réka TarcsaiDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Adrienne LukácsDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Erzsébet BarcsayDepartment of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Katalin Szomor *Department of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary.
Mária Takács *Department of Microbiological Reference Laboratories, National Center for Public Health and Pharmacy, Budapest, 1097, Hungary. takacs.maria@semmelweis.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic led to widespread public health interventions that significantly affected the transmission of various pathogens, including enteroviruses (EVs). EVs exhibit considerable genetic diversity and can cause clinical manifestations ranging from mild illnesses to severe diseases. Our present study aimed to evaluate the diversity of circulating EV types in Hungary and assess the impact of lockdown measures on EV prevalence based on testing clinical samples obtained from symptomatic patients.

methodsAs part of the routine enterovirus diagnosis, we conducted quantitative reverse transcription polymerase chain reaction (RT-qPCR) on clinical samples obtained from patients presenting with symptoms corresponding to EV infection. Positive samples were then subjected to virus isolation in cell culture and next-generation sequencing (NGS). Phylogenetic analysis was performed to place the newly generated sequences within the global diversity of EV strains for comparison.

resultsDuring this period, an overall number of 125 patients tested positive for EVs, mostly children under the age of 15 years. The most common symptoms were fever, hand-foot-mouth disease, encephalitis, and meningitis. The temporal distribution of EV-positive cases showed strong seasonality, with peaks in the summer and autumn months. The lowest number of confirmed cases occurred during the lockdown years, attributed to limited sample collection and reduced personal contacts. However, following the easing of restrictions, the number of cases significantly increased, with the highest incidence observed in 2022. The distribution of EV genotypes shifted notably after easing the lockdowns. While only coxsackievirus (CV)A6 was detected during 2021, a broader range of genotypes emerged afterwards, including CVA10, CVA16, echovirus E9, and E11.

conclusionsNext-generation sequencing analysis revealed notable genotypic diversity, providing valuable insights into the evolution of EVs in Hungary and across Europe. These findings underscore the importance of continued surveillance of enterovirus infections, particularly in the context of pandemic recovery, as the shifting EV genotype landscape may impact disease severity and spread, highlighting the need for adaptive public health responses.

Indexed as

COVID-19EnterovirusEnterovirus InfectionsAdolescentAdultAgedChildChild, PreschoolFemaleGenetic VariationHigh-Throughput Nucleotide SequencingHumansHungaryInfantMaleMiddle AgedCOVID-19 lockdownEnterovirusesGenetic diversityPandemicPhylogenetic analysis

Identifiers

PMID40555984
PMCPMC12186400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.